US Bancorp’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-5,687
| Closed | -$71K | – | 3731 |
|
|
2016
Q4 | $71K | Buy |
5,687
+554
| +11% | +$6.67K | ﹤0.01% | 2282 |
|
|
2016
Q3 | $70K | Sell |
5,133
-5,516
| -52% | -$55.4K | ﹤0.01% | 2274 |
|
|
2016
Q2 | $79K | Buy |
10,649
+51
| +0.5% | +$383 | ﹤0.01% | 2185 |
|
|
2016
Q1 | $68K | Sell |
10,598
-128
| -1% | -$717 | ﹤0.01% | 2229 |
|
|
2015
Q4 | $67K | Sell |
10,726
-802
| -7% | -$5.26K | ﹤0.01% | 2298 |
|
|
2015
Q3 | $67K | Sell |
11,528
-1,949
| -14% | -$15K | ﹤0.01% | 2310 |
|
|
2015
Q2 | $112K | Sell |
13,477
-210
| -2% | -$1.86K | ﹤0.01% | 2082 |
|
|
2015
Q1 | $112K | Sell |
13,687
-4,452
| -25% | -$32.9K | ﹤0.01% | 2096 |
|
|
2014
Q4 | $125K | Buy |
18,139
+9,597
| +112% | +$60K | ﹤0.01% | 2002 |
|
|
2014
Q3 | $47K | Buy |
8,542
+1,274
| +18% | +$7.44K | ﹤0.01% | 2519 |
|
|
2014
Q2 | $46K | Sell |
7,268
-1,299
| -15% | -$8.93K | ﹤0.01% | 2533 |
|
|
2014
Q1 | $69K | Buy |
8,567
+2,646
| +45% | +$20.6K | ﹤0.01% | 2332 |
|
|
2013
Q4 | $41K | Sell |
5,921
-1,376
| -19% | -$7.43K | ﹤0.01% | 2503 |
|
|
2013
Q3 | $134K | Sell |
7,297
-79
| -1% | -$1.53K | ﹤0.01% | 1901 |
|
|
2013
Q2 | $129K | Buy |
+7,376
| New | +$131K | ﹤0.01% | 1885 |
|
Other funds holding ARIA
US Bancorp's ARIA Position: Q1 2017 in Review
US Bancorp sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 5,687 shares — an estimated $71K sold.
US Bancorp first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $134K in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- US Bancorp reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- US Bancorp sold 5,687 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $71K.
- US Bancorp first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- US Bancorp's Ariad Pharmaceuticals Inc position peaked at $134K in Q3 2013.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on US Bancorp's 13F filing for Q1 2017, filed 3 May 2017.